ClinicalTrials.gg
Not yet recruitingNCT07701148HEREUpdated Oct 27, 2026

HERE: Health Empowerment and Resources After Pregnancy

An interventional study of Longitudinal patient navigation and Standard care in Cardiovascular Health, sponsored by Boston Medical Center. Not yet recruiting at 1 site in United States. Open to female participants aged 23 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Boston Medical Center · Not applicable, Interventional, and Health services research

Updated Oct 27, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
23 Years and older
Sex
Female
01

Study summary

This study will examine whether a patient navigation program can help improve long-term heart health among people who experienced high blood pressure disorders during pregnancy at Boston Medical Center (BMC). Conditions such as preeclampsia and other hypertensive disorders of pregnancy increase a person's risk of developing cardiovascular disease later in life. However, many patients do not receive timely follow-up care after pregnancy, especially once routine postpartum care ends.

about 60 participants will be randomly assigned to one of two groups. One group will receive standard care, which includes clinician-directed counseling about cardiovascular risk and recommendations for follow-up care. The other group will receive support from a patient navigator in addition to standard care. Patient navigators, also known as Community Wellness Advocates (CWAs), are trained staff who help patients connect with health services, understand their health risks, and navigate the healthcare system.

The main goals of the study are to determine whether this navigation program is practical to implement and acceptable to patients and healthcare providers. Researchers will also examine whether the program improves follow-up with primary care, cardiovascular risk assessment, and engagement in heart-healthy behaviors. Information will be collected from medical records, surveys, and interviews with participants and healthcare staff. Participants will be followed for one year

02

Conditions studied

  • Cardiovascular Health

Keywords

  • Community wellness advocate
  • Remote blood pressure monitoring
  • Postpartum
  • Hypertensive disorders of pregnancy
03

In context

Lead sponsor

Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.

Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
23 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gave birth at Boston Medical Center (BMC) in the past 4 months
  • Diagnosis of ≥1 hypertensive disorder of pregnancy during their most recent pregnancy
  • Active prescription for ≥1 antihypertensive medication
  • Scheduled for follow-up in the postpartum bridge clinic at BMC
  • Planning to continue using Boston Medical Center for their health care
  • Able and willing to provide and contact information in English, Spanish, or Haitian Creole (CWA will use hospital interpreter services as needed to communicate with patients with a language preference other than English)

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with cardiovascular disease
  • Planning pregnancy in next 3 months
  • Planning to move out of Massachusetts within the postpartum year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Postpartum patient navigation

    Participants randomized to this intervention arm will receive longitudinal patient navigation from a Community Wellness Advocate (CWA) who will provide ongoing support after discharge at \~6-8 weeks post partum from the perinatal remote blood pressure monitoring (RBPM) program.

    Other: Longitudinal patient navigation

  • Active comparator
    Standard of care

    Participants randomized to this control arm will continue with standard care for a year after discharge from the hospital's perinatal RBPM program at \~6-8 weeks postpartum.

    Other: Standard care

Interventions

  • OtherLongitudinal patient navigation

    A Community Wellness Advocate (CWA) will provide longitudinal patient navigation-proactive check-ins, assistance with appointment attendance scheduling and planning, identification of barriers to care, follow-up after missed appointments, mental health and social needs screening, and connections to appropriate resources. The CWA will serve as a consistent point of contact throughout the postpartum year.

  • OtherStandard care

    Standard care includes education on postpartum hypertension, a blood pressure cuff for self-monitoring, and assistance with scheduling follow-up care, including referral to a postpartum bridge clinic in General Internal Medicine.

06

What researchers measure

Primary outcomes

  1. Acceptability of the intervention

    Acceptability, the perception among stakeholders that the intervention is agreeable, will be measured using the 4-item Acceptability of Intervention Measure. Responses will be collected on a 5-point Likert scale (1-5), and the total score will range from 4-20. Total score will be evaluated as a continuous outcome with higher scores indicating greater acceptability. Results will be separately analyzed among participants, navigators, and other clinical staff.

    Time frame: 4-6 and 12 months postpartum

  2. Feasibility of the intervention

    Feasibility, the extent to which the intervention can be carried out, will be measured using the 4-item Feasibility of Intervention Measure. Responses will be collected on a 5-point Likert scale (1-5), and the total score will range from 4-20. Total score will be evaluated as a continuous outcome with higher scores indicating greater feasibility.

    Time frame: 4-6 and 12 months postpartum

  3. Fidelity of the intervention- Penetration

    Penetration or "reach" is defined as the percentage of eligible individuals who were screened. This fidelity related metric will be assessed using a protocol-based checklist and electronic health record data for reference monthly

    Time frame: monthly for 12 months postpartum

  4. Fidelity of the intervention- Adherence

    Adherence is defined as the percentage of enrolled participants who were supported by the navigator. This fidelity related metric will be assessed using a protocol-based checklist and electronic health record data for reference monthly.

    Time frame: monthly for 12 months postpartum

Secondary outcomes

  1. Participation Satisfaction

    Satisfaction will be measured using the 18-item Patient Satisfaction Questionnaire (PSQ-18). Each item is rated on a 5-point Likert scale (strongly agree to strongly disagree), and items are grouped into 7 dimensions of care: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience. Each dimension is measured by 2-4 items. After reverse-coding negatively worded items, we will calculate the mean response score (1-5) for each dimension, with higher scores indicating greater satisfaction with care.

    Time frame: 4-6 and 12 months postpartum

  2. Linkage to Primary Care

    The measure will be the percentage of participants with a completed primary care visit, excluding Bridge clinic appointments, occurring between \>6 weeks and 1 year postpartum.

    Time frame: 4-6 and 12 months postpartum

  3. Cardiovascular Health (CVH)

    CVH will be defined using the American Heart Association's Life's Essential 8 construct, which scores each of 8 domains from 0 to 100 and generates an overall CVH score as the unweighted average of the 8 component scores (0 = worst, 100 = best heart health). The 8 components of CVH are- diet, physical activity, sleep, nicotine exposure, body mass index, blood lipids, blood glucose, and blood pressure. Diet, physical activity, sleep, and nicotine exposure will be assessed by self-report via survey. Body mass index, blood lipids, blood glucose, and blood pressure will be drawn from the electronic health record (using values closest to the assessment window), and EHR-documented tobacco use will corroborate self-reported nicotine exposure. Each domain subscore (0-100) will be calculated per Life's Essential 8 and generate the overall CVH score as the unweighted average of the 8 domains.

    Time frame: 2, 4-6, and 12 months postpartum

  4. Cardiovascular Disease (CVD) Risk Assessment

    Cardiovascular disease risk assessment will be defined as completion of both glycemic control testing (OGTT or A1c) and lipids testing between \>6 weeks and 1 year postpartum. This will be assessed from the electronic health record based on completed lab testing.

    Time frame: 12 months postpartum

  5. Patient Activation

    Patient activation, a composite measure of knowledge, skills, and confidence to become actively engaged in one's own health care, will be assessed using the 10-item Consumer Health Activation Index (CHAI). Scores range from 0-100 and are categorized as follows: 0-79 = Low activation; 80-94 = Moderate activation; 95-100 = High activation.

    Time frame: 2, 4-6, and 12 months postpartum

  6. Bridge Clinic Attendance

    The measure will be the percentage of participants with a completed bridge clinic appointment between \>6 weeks and 4 months postpartum.

    Time frame: 2, 4-6, and 12 months postpartum

  7. CVD risk perception

    Participants will be asked about their level of concern for their future heart health, on a 4-point scale. Descriptive statistics will be calculated on this outcome as an ordered categorical variable.

    Time frame: 2, 4-6, and 12 months postpartum

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, last on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 14, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
moved 2 times, Sep 29, 2026 – Oct 27, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedGave birth at Boston Medical Center (BMC) in the past 24 months
Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    Start date Nov 2026→Dec 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedGave birth at Boston Medical Center (BMC) in the past 24 months
    + 1 other change: verification date
  2. Sep 29, 2026
    Start date Sep 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07701148
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Dec 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Mara Murray Horwitz, MD, MPH
Contact
mara.murrayhorwitz@bmc.org
617 638 8034
Ruth Rodriguez, BS
Contact
ruth.rodriguez2@bmc.org
Mara Murray Horwitz, MD, MPH
principal investigator · Boston Medical Center, General Internal Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion